It was reported that during continuous renal replacement therapy on a pediatric patient using a prismaflex control unit and four (4) units of a prismaflex hf20, self-test failure (4, pressure pod/sensor issue) alarms were generated and at least one of the treatment was ended without the extracorporeal blood being returned to the patient.A blood transfusion was performed on the patient.No additional information is available.No additional information is available.
|
Date of event: the occurrence date was reported to be between (b)(6) 2021.Prismaflex hf20 set has been temporarily approved for use in the us under emergency use authorization (b)(4) to provide continuous renal replacement therapy (crrt) to treat low weight (8 kg to 20 kg) and low blood volume patients or patients who have acute renal failure, fluid overload, or both, and who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the coronavirus disease 2019 (covid-19) pandemic.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.The device was not received for evaluation; however, pictures were presented for inspection.The visual inspection of the provided photos did not identifying any specific defect on the impacted set.Therefore, it is undetermined if a product defect caused or contributed to the reported alarm generated by the control unit.Should additional relevant information become available, a supplemental report will be submitted.
|